Loading institutional data...
Loading institutional data...
Held by 190 of 5,944 reporting institutions (91th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $3.37 today, the market must believe free cash flow compounds 35.8%/yr for a decade (off $3M normalized FCF).
The market's 35.8% is more optimistic than its 1-yr track record.
2-stage DCF · 0.38B shares · net debt -$792M
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $10M buybacks = $10M returned on $149000 FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 9 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -1%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 9 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2022 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.6M 100.0% | $117.6M 100.0% | $87.2M 100.0% | $86.7M 100.0% | $64.6M 100.0% | $46.7M 100.0% | $23.8M 100.0% | $12.1M 100.0% | $3.1M 100.0% |
| Gross Profit | $62.8M 42.8% | $25.2M 21.4% | $11.9M 13.7% | $15.4M 17.8% | -$17.6M -27.3% | -$25.8M -55.3% | -$17.6M -74.1% | $6.2M 51.3% | $1.6M 50.0% |
| Research & Development | $4.4M 3.0% | $4.2M 3.6% | $5.8M 6.7% | $13.1M 15.1% | $21.8M 33.8% | $20.4M 43.6% | $12.2M 51.2% | $1.8M 15.0% | $0 0.0% |
| Selling, General & Admin | $42.0M 28.7% | $46.5M 39.5% | $49.5M 56.7% | $67.7M 78.0% | $90.9M 140.8% | $80.6M 172.5% | $81.5M 343.1% | $13.3M 110.1% | $4.9M 155.8% |
| Total Operating Expenses | $80.2M 54.7% | $101.7M 86.5% | $96.7M 110.9% | $126.9M 146.2% | $274.4M 425.0% | $193.6M 414.3% | $135.7M 571.4% | $26.7M 219.9% | $7.7M 244.5% |
| Operating Income | -$17.4M -11.9% | -$76.5M -65.1% | -$84.8M -97.2% | -$111.4M -128.4% | -$292.0M -452.2% | -$219.4M -469.6% | -$153.3M -645.5% | -$20.4M -168.7% | -$6.1M -194.5% |
| Interest Expense | — | — | — | $13K 0.0% | $27K 0.0% | $186K 0.4% | $1.2M 5.2% | $139K 1.1% | $101K 3.2% |
| Interest & Investment Income | — | — | — | $22.6M 26.0% | $9.1M 14.1% | $18.6M 39.8% | $29.2M 123.0% | $220K 1.8% | $4K 0.1% |
| Other Income (Expense), net | $275K 0.2% | $113.1M 96.2% | $11.1M 12.8% | -$9.6M -11.0% | $163.5M 253.2% | $146.1M 312.8% | $1.32B 5554.7% | -$478K -3.9% | $3.8M 120.0% |
| Pretax Income | -$17.1M -11.7% | $36.6M 31.1% | -$73.7M -84.4% | -$121.0M -139.5% | -$128.5M -199.1% | -$73.3M -156.8% | $1.17B 4909.2% | -$20.9M -172.6% | -$2.3M -74.5% |
| Income Tax Expense | -$14.2M -9.7% | -$3.4M -2.9% | -$3.2M -3.7% | $34.2M 39.4% | -$431K -0.7% | $1.3M 2.9% | $0 0.0% | $0 0.0% | -$862K -27.4% |
| Net Income | -$2.9M -2.0% | $40.0M 34.0% | -$73.9M -84.7% | -$168.7M -194.5% | -$396.1M -613.5% | -$73.1M -156.5% | $1.17B 4911.6% | -$21.6M -178.5% | -$1.5M -47.1% |
| Per Share | |||||||||
| EPS (Basic) | $-0.02 | $0.11 | $-0.19 | $-0.45 | $-1.07 | $-0.21 | $3.76 | $-0.12 | $-0.01 |
| EPS (Diluted) | $-0.02 | $0.11 | $-0.19 | $-0.45 | $-1.07 | $-0.21 | $3.33 | $-0.12 | $-0.01 |
| Weighted Avg Shares (Basic) | 383.5M | 382.1M | 381.0M | 377.0M | 370.4M | 351.6M | 310.1M | 172.3M | 134.8M |
| Weighted Avg Shares (Diluted) | 383.5M | 385.6M | 381.0M | 377.0M | 370.4M | 351.6M | 342.8M | 172.3M | 176.8M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Where each multiple sits in its own 9-yr range · 39th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 9-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Profit | 51.3 | -74.1 | -55.3 | -27.3 | 17.8 | 13.7 | 21.4 | 42.8 |
| R&D | 15.0 | 51.2 | 43.6 | 33.8 | 15.1 | 6.7 | 3.6 | 3.0 |
| SG&A | 110.1 | 343.1 | 172.5 | 140.8 | 78.0 | 56.7 | 39.5 | 28.7 |
| Operating Income | -168.7 | -645.5 | -469.6 | -452.2 | -128.4 | -97.2 | -65.1 | -11.9 |
| Income Tax | 0.0 | 0.0 | 2.9 | -0.7 | 39.4 | -3.7 | -2.9 | -9.7 |
| Net Income | -178.5 | 4911.6 | -156.5 | -613.5 | -194.5 | -84.7 | 34.0 | -2.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CRON: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| CRON | $1.3B | — | — | 8.8× | 24.6% | 42.8% | -6.4% | -0.9% | -0.9% | — | 190 |
Peers = companies sharing CRON's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.